Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November 2019 in the country’s eastern provinces, to counter the current outbreak.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Five Prime Therapeutics Inc. will eliminate 70 jobs while undergoing a restructuring to extend the company’s cash runway.
Roche Vice Chairman Andre Hoffman is warning that short-term thinking is killing the planet and that corporations must engage in long-term sustainable strategies that limit any environmental harm.
Purdue Pharma LP will ask a U.S. Bankruptcy Judge to pause litigation against the company and ownership over the objections of U.S. states that allege the OxyContin maker is trying to protect the controlling Sackler family.
Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.
International donors agreed to pledge 13.8 billion euros ($15.21 billion) to tackle AIDS, said French President Emmanuel Macron.
UCB will acquire U.S.-based Ra Pharmaceuticals in a $2.1 billion deal that will enable the Belgian drugmaker to offer new treatment options for several rare diseases in neurology and immunology.
Cambridge, Mass.-based bluebird bio and Bagsvaerd, Denmark-based Novo Nordisk agreed to develop next-generation genome editing therapies for genetic diseases, including hemophilia.
W2O – a leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector – acquired Arcus Medica, a recognized leader in medical and scientific communications.
About a quarter of the dollars spent on healthcare in the United States may be wasted, a new analysis suggests.